Suggested remit: To appraise the clinical and cost effectiveness of brolucizumab within its marketing authorisation for treating diabetic macular oedema.
Status In progress
Process STA 2018
ID number 3902

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
06 October 2021 - 03 November 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
18 February 2021 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance